A Multicentric, International, Randomized, Double-Blind, Placebo-Controlled, Phase II/III (MYODA-INT) Study to Evaluate the Safety and Efficacy of a Sarconeos Dose in Ambulant Boys with Duchenne Myopathy
Phase of Trial: Phase II/III
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Sarconeos (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Acronyms MYODA-INT
- Sponsors Biophytis
- 31 Oct 2019 According to an Biophytis media release, the company expects to file IND with FDA in Q4 2019.
- 02 Oct 2019 According to an Biophytis media release, this trial is expected to commence in 2020.
- 02 Oct 2019 According to an Biophytis media release, two posters highlighting the innovative MYODA clinical trial design will be presented at the 24th International Annual Congress of the World Muscle Society (WMS).